查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1594053

腦膜炎雙球菌疫苗市場：按類型、類別、劑量類型、目標群體、最終用戶分類 - 2025-2030 年全球預測

Meningococcal Vaccines Market by Type (Combination Vaccines, Conjugate Vaccines, Men B Vaccines), Category (Intramuscular, Subcutaneous), Dosage Type, Target Group, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年腦膜炎雙球菌疫苗市場規模為54.5億美元，預計2024年將達59.5億美元，複合年成長率為10.50%，預計2030年將達到109.7億美元。

腦膜炎雙球菌疫苗市場範圍是生產和部署預防腦膜炎雙球菌感染疾病的疫苗，主要針對青少年和特定高風險族群。這項需求源自於腦膜炎雙球菌病菌感染造成的嚴重健康威脅，這種感染會造成腦膜炎和敗血症等毀滅性後果。這些疫苗主要用於公共衛生免疫策略，特別建議用於流行地區和具有特定健康風險的人。最終用途包括醫療保健提供者、診所、政府衛生機構、研究機構等。主要成長動力包括政府對免疫計劃的興趣增加、疾病風險意識的提高以及疫苗配方的技術進步。值得注意的是，COVID-19 大流行強化了疫苗接種的重要性，並間接提高了投資和意識，為市場相關人員提供了擴大支持和教育力度的機會。目前的商機包括為疾病負擔高的新興國家開發更便宜、更容易取得的疫苗，以及疫苗儲存和供應技術的創新。然而，低收入地區對疫苗接種猶豫不決、監管障礙和後勤障礙等挑戰阻礙了市場擴張。此外，在更廣泛的感染疾病領域，來自其他生物製藥和預防性治療的競爭帶來了市場飽和的風險。創新的要點是提高疫苗功效、提高血清群覆蓋率以及改進遞送機制（例如無針選擇）。個人化醫療和基於 mRNA 的疫苗也呈現成長趨勢，市場可以探索。市場前景廣闊但複雜，我們正在尋求利用全球免疫領域的新機遇，平衡戰略支持工作，例如投資研究和與公共衛生機構合作，我們需要利用它並克服其固有的問題。

主要市場統計
基準年[2023] 54.5億美元
預測年份 [2024] 59.5億美元
預測年份 [2030] 109.7億美元
複合年成長率（%） 10.50%

市場動態：快速發展的腦膜炎雙球菌疫苗市場的關鍵市場洞察

供需的動態交互作用正在改變腦膜炎球菌疫苗市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，並了解消費行為及其對製造成本的影響，並更清楚地了解對採購趨勢的影響。

  • 市場促進因素
    • 全球腦膜炎發生率不斷上升
    • 活性化研發活動和正在進行中的疫苗開發
    • 加強免疫計畫和政府針對腦膜炎雙球菌疾病的努力
  • 市場限制因素
    • 生產成本高
  • 市場機會
    • 改善新興國家細菌性腦膜炎的發生率和監測系統
    • 加強合作研究和夥伴關係以支持疫苗開發
  • 市場挑戰
    • 腦膜炎雙球菌疫苗的限制和副作用

波特的五力：駕馭腦膜炎雙球菌疫苗市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解腦膜炎雙球菌疫苗市場的外部影響

外部宏觀環境因素在塑造腦膜炎雙球菌疫苗市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解腦膜炎雙球菌疫苗市場的競爭格局

對腦膜炎雙球菌疫苗市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣腦膜炎雙球菌疫苗市場供應商的績效評估

FPNV定位矩陣是評估腦膜炎雙球菌疫苗市場供應商的關鍵工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪了腦膜炎雙球菌疫苗市場的成功之路

對於旨在加強在全球市場的影響力的公司來說，對腦膜炎雙球菌疫苗市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5.產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 全球腦膜炎發生率增加
      • 增加研發活動和正在進行的疫苗開發
      • 加強免疫計畫和政府針對病菌感染疾病的努力
    • 抑制因素
      • 腦膜炎雙球菌疫苗生產成本高
    • 機會
      • 改善新興國家細菌性腦膜炎的發生率和監測系統
      • 加強合作和夥伴關係以支持疫苗開發
    • 任務
      • 腦膜炎雙球菌疫苗的限制和副作用
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章腦膜炎雙球菌疫苗市場：依類型

  • 聯合疫苗
    • 混合體
    • 梅尼特里克斯
  • 結合疫苗
    • 梅納克特拉
    • 梅納夫里瓦克
    • 腦膜炎科技
    • 門朱蓋特
    • 門貝奧
    • 尼斯巴克C
    • 尼門里克斯
    • NmVac4-DT
  • 男性 B 疫苗
    • 貝克塞洛
    • 托門巴
  • 多醣體疫苗
    • 門塞瓦克斯
    • 梅農宗
    • ＮｍＶａｃ４

第7章腦膜炎雙球菌疫苗市場：依類別

  • 肌肉注射
  • 皮下的

第8章按劑量類型分類的腦膜炎雙球菌疫苗市場

  • 額外疫苗接種
  • 初級疫苗接種

第9章目標族群腦膜炎雙球菌疫苗市場

  • 成人用
  • 青春期前的
  • 青少年

第 10 章 腦膜炎雙球菌疫苗市場：依最終使用者分類

  • 醫院藥房
  • 小兒科診所
  • 零售藥房

第11章美洲腦膜炎球菌疫苗市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第12章亞太地區腦膜炎雙球菌疫苗市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第13章歐洲、中東和非洲腦膜炎雙球菌疫苗市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bavarian Nordic A/S
  • Bharat Biotech Ltd.
  • Bio-Manguinhos
  • Bio-Med（P）Limited
  • CanSino Biologics Inc.
  • Chongqing Zhifei Biological Products Co., Ltd.
  • Emergent BioSolutions Inc.
  • GlaxoSmithKline PLC
  • Incepta Pharmaceuticals Ltd.
  • Merck & Co., Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Nanolek, LLC
  • Novartis AG
  • Panacea Biotec Ltd.
  • Petrovax Pharm
  • Pfizer Inc.
  • Sanofi SA
  • Serum Institute of India Pvt. Ltd.
  • Shanghai Fosun Pharmaceutical（Group）Co., Ltd.
  • Sinovac Biotech Ltd.
  • SK bioscience
  • Taj Pharmaceuticals Limited
  • Vabiotech
  • Walvax Biotechnology Co., Ltd.
Product Code: MRR-430D42AA101A

The Meningococcal Vaccines Market was valued at USD 5.45 billion in 2023, expected to reach USD 5.95 billion in 2024, and is projected to grow at a CAGR of 10.50%, to USD 10.97 billion by 2030.

The scope of the meningococcal vaccines market entails production and deployment of vaccines designed to prevent infections caused by Neisseria meningitidis, targeting primarily adolescents and young adults as well as certain high-risk groups. The necessity arises from the serious health threat posed by meningococcal disease, which can result in devastating outcomes such as meningitis and septicemia. These vaccines are employed primarily in public health immunization strategies and are specifically recommended in outbreak-prone regions and for individuals with specific health risks. The end-use scope encompasses healthcare providers, clinics, governmental health organizations, and research institutions. Key growth drivers include heightened government focus on immunization programs, rising awareness about the disease's risks, and technological advancements in vaccine formulations. Notably, the COVID-19 pandemic reinforced the importance of vaccination, indirectly boosting investments and awareness, presenting opportunities for market players to expand outreach and educational efforts. Current opportunities include developing more affordable and accessible vaccine options for developing countries, where disease burden is often higher, as well as innovations in vaccine storage and delivery technologies. However, challenges such as vaccine hesitancy, regulatory hurdles, and logistical barriers in low-income regions stifle market expansion. Additionally, the competition from other biologic and preventive treatments in broader infectious disease domains presents market saturation risks. Innovations largely lie in enhancing vaccine efficacy, broadening serogroup coverage, and improving delivery mechanisms, such as needle-free options. There is a rising trend towards personalized medicine and mRNA-based vaccines, which the market can explore. The meningococcal vaccines market showcases a promising yet complex dynamic that requires balancing strategic outreach with investment in research and collaboration with public health entities to overcome inherent limitations while capitalizing on emerging opportunities in the global immunization landscape.

KEY MARKET STATISTICS
Base Year [2023] USD 5.45 billion
Estimated Year [2024] USD 5.95 billion
Forecast Year [2030] USD 10.97 billion
CAGR (%) 10.50%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Meningococcal Vaccines Market

The Meningococcal Vaccines Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing Incidence of Meningitis Across the World
    • Rising R&D Activities and Vaccines Developments in the Pipeline
    • Rising Immunization Programs and Government Initiatives for Meningococcal Diseases
  • Market Restraints
    • High Cost of Meningococcal Vaccines Production
  • Market Opportunities
    • Incidence of Bacterial Meningitis in Emerging Countries Coupled with Improvement in Surveillance System
    • Elevation of Collaborations and Partnerships to Support the Development of the Vaccines
  • Market Challenges
    • Limitations and Side Effects Associated with Meningococcal Vaccines

Porter's Five Forces: A Strategic Tool for Navigating the Meningococcal Vaccines Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Meningococcal Vaccines Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Meningococcal Vaccines Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Meningococcal Vaccines Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Meningococcal Vaccines Market

A detailed market share analysis in the Meningococcal Vaccines Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Meningococcal Vaccines Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Meningococcal Vaccines Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Meningococcal Vaccines Market

A strategic analysis of the Meningococcal Vaccines Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Meningococcal Vaccines Market, highlighting leading vendors and their innovative profiles. These include Astellas Pharma Inc., AstraZeneca PLC, Bavarian Nordic A/S, Bharat Biotech Ltd., Bio-Manguinhos, Bio-Med (P) Limited, CanSino Biologics Inc., Chongqing Zhifei Biological Products Co., Ltd., Emergent BioSolutions Inc., GlaxoSmithKline PLC, Incepta Pharmaceuticals Ltd., Merck & Co., Inc., Mitsubishi Tanabe Pharma Corporation, Nanolek, LLC, Novartis AG, Panacea Biotec Ltd., Petrovax Pharm, Pfizer Inc., Sanofi S.A., Serum Institute of India Pvt. Ltd., Shanghai Fosun Pharmaceutical (Group) Co., Ltd., Sinovac Biotech Ltd., SK bioscience, Taj Pharmaceuticals Limited, Vabiotech, and Walvax Biotechnology Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the Meningococcal Vaccines Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Combination Vaccines, Conjugate Vaccines, Men B Vaccines, and Polysaccharide Vaccines. The Combination Vaccines is further studied across MenHibrix and Menitorix. The Conjugate Vaccines is further studied across Menactra, MenAfriVac, Meningitec, Menjugate, Menveo, NeisVac-C, Nimenrix, and NmVac4-DT. The Men B Vaccines is further studied across Bexsero and Trumenba. The Polysaccharide Vaccines is further studied across Mencevax, Menomune, and NmVac4.
  • Based on Category, market is studied across Intramuscular and Subcutaneous.
  • Based on Dosage Type, market is studied across Booster Vaccination and Primary Vaccination.
  • Based on Target Group, market is studied across Adult, Preteen, and Teenager.
  • Based on End-User, market is studied across Hospital Pharmacies, Pediatric Clinic, and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing Incidence of Meningitis Across the World
      • 5.1.1.2. Rising R&D Activities and Vaccines Developments in the Pipeline
      • 5.1.1.3. Rising Immunization Programs and Government Initiatives for Meningococcal Diseases
    • 5.1.2. Restraints
      • 5.1.2.1. High Cost of Meningococcal Vaccines Production
    • 5.1.3. Opportunities
      • 5.1.3.1. Incidence of Bacterial Meningitis in Emerging Countries Coupled with Improvement in Surveillance System
      • 5.1.3.2. Elevation of Collaborations and Partnerships to Support the Development of the Vaccines
    • 5.1.4. Challenges
      • 5.1.4.1. Limitations and Side Effects Associated with Meningococcal Vaccines
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Meningococcal Vaccines Market, by Type

  • 6.1. Introduction
  • 6.2. Combination Vaccines
    • 6.2.1. MenHibrix
    • 6.2.2. Menitorix
  • 6.3. Conjugate Vaccines
    • 6.3.1. Menactra
    • 6.3.2. MenAfriVac
    • 6.3.3. Meningitec
    • 6.3.4. Menjugate
    • 6.3.5. Menveo
    • 6.3.6. NeisVac-C
    • 6.3.7. Nimenrix
    • 6.3.8. NmVac4-DT
  • 6.4. Men B Vaccines
    • 6.4.1. Bexsero
    • 6.4.2. Trumenba
  • 6.5. Polysaccharide Vaccines
    • 6.5.1. Mencevax
    • 6.5.2. Menomune
    • 6.5.3. NmVac4

7. Meningococcal Vaccines Market, by Category

  • 7.1. Introduction
  • 7.2. Intramuscular
  • 7.3. Subcutaneous

8. Meningococcal Vaccines Market, by Dosage Type

  • 8.1. Introduction
  • 8.2. Booster Vaccination
  • 8.3. Primary Vaccination

9. Meningococcal Vaccines Market, by Target Group

  • 9.1. Introduction
  • 9.2. Adult
  • 9.3. Preteen
  • 9.4. Teenager

10. Meningococcal Vaccines Market, by End-User

  • 10.1. Introduction
  • 10.2. Hospital Pharmacies
  • 10.3. Pediatric Clinic
  • 10.4. Retail Pharmacies

11. Americas Meningococcal Vaccines Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Meningococcal Vaccines Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Meningococcal Vaccines Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Astellas Pharma Inc.
  • 2. AstraZeneca PLC
  • 3. Bavarian Nordic A/S
  • 4. Bharat Biotech Ltd.
  • 5. Bio-Manguinhos
  • 6. Bio-Med (P) Limited
  • 7. CanSino Biologics Inc.
  • 8. Chongqing Zhifei Biological Products Co., Ltd.
  • 9. Emergent BioSolutions Inc.
  • 10. GlaxoSmithKline PLC
  • 11. Incepta Pharmaceuticals Ltd.
  • 12. Merck & Co., Inc.
  • 13. Mitsubishi Tanabe Pharma Corporation
  • 14. Nanolek, LLC
  • 15. Novartis AG
  • 16. Panacea Biotec Ltd.
  • 17. Petrovax Pharm
  • 18. Pfizer Inc.
  • 19. Sanofi S.A.
  • 20. Serum Institute of India Pvt. Ltd.
  • 21. Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
  • 22. Sinovac Biotech Ltd.
  • 23. SK bioscience
  • 24. Taj Pharmaceuticals Limited
  • 25. Vabiotech
  • 26. Walvax Biotechnology Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. MENINGOCOCCAL VACCINES MARKET RESEARCH PROCESS
  • FIGURE 2. MENINGOCOCCAL VACCINES MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES MENINGOCOCCAL VACCINES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES MENINGOCOCCAL VACCINES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. MENINGOCOCCAL VACCINES MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. MENINGOCOCCAL VACCINES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. MENINGOCOCCAL VACCINES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. MENINGOCOCCAL VACCINES MARKET DYNAMICS
  • TABLE 7. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY MENHIBRIX, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY MENITORIX, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY MENACTRA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY MENAFRIVAC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY MENINGITEC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY MENJUGATE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY MENVEO, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY NEISVAC-C, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY NIMENRIX, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY NMVAC4-DT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY BEXSERO, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY TRUMENBA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY MENCEVAX, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY MENOMUNE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY NMVAC4, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY BOOSTER VACCINATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY PRIMARY VACCINATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY PRETEEN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY TEENAGER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY PEDIATRIC CLINIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. AMERICAS MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
  • TABLE 49. AMERICAS MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 50. AMERICAS MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 51. AMERICAS MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. AMERICAS MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
  • TABLE 53. AMERICAS MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 54. AMERICAS MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 55. ARGENTINA MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. ARGENTINA MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 57. ARGENTINA MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 58. ARGENTINA MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
  • TABLE 59. ARGENTINA MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 60. ARGENTINA MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 61. ARGENTINA MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. ARGENTINA MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
  • TABLE 63. ARGENTINA MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 64. BRAZIL MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. BRAZIL MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 66. BRAZIL MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 67. BRAZIL MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
  • TABLE 68. BRAZIL MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 69. BRAZIL MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 70. BRAZIL MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. BRAZIL MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
  • TABLE 72. BRAZIL MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. CANADA MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. CANADA MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 75. CANADA MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 76. CANADA MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
  • TABLE 77. CANADA MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 78. CANADA MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 79. CANADA MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. CANADA MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
  • TABLE 81. CANADA MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 82. MEXICO MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. MEXICO MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 84. MEXICO MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 85. MEXICO MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
  • TABLE 86. MEXICO MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 87. MEXICO MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 88. MEXICO MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. MEXICO MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
  • TABLE 90. MEXICO MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. UNITED STATES MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. UNITED STATES MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 93. UNITED STATES MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 94. UNITED STATES MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
  • TABLE 95. UNITED STATES MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 96. UNITED STATES MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED STATES MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED STATES MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED STATES MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED STATES MENINGOCOCCAL VACCINES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 111. AUSTRALIA MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. AUSTRALIA MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 113. AUSTRALIA MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 114. AUSTRALIA MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
  • TABLE 115. AUSTRALIA MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 116. AUSTRALIA MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 117. AUSTRALIA MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. AUSTRALIA MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
  • TABLE 119. AUSTRALIA MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 120. CHINA MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. CHINA MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 122. CHINA MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 123. CHINA MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
  • TABLE 124. CHINA MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 125. CHINA MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 126. CHINA MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. CHINA MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
  • TABLE 128. CHINA MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 129. INDIA MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. INDIA MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 131. INDIA MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 132. INDIA MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
  • TABLE 133. INDIA MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 134. INDIA MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 135. INDIA MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. INDIA MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
  • TABLE 137. INDIA MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 138. INDONESIA MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. INDONESIA MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 140. INDONESIA MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 141. INDONESIA MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
  • TABLE 142. INDONESIA MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 143. INDONESIA MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 144. INDONESIA MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. INDONESIA MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
  • TABLE 146. INDONESIA MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 147. JAPAN MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. JAPAN MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 149. JAPAN MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 150. JAPAN MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
  • TABLE 151. JAPAN MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 152. JAPAN MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 153. JAPAN MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. JAPAN MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
  • TABLE 155. JAPAN MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 156. MALAYSIA MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. MALAYSIA MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 158. MALAYSIA MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 159. MALAYSIA MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
  • TABLE 160. MALAYSIA MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 161. MALAYSIA MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 162. MALAYSIA MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. MALAYSIA MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
  • TABLE 164. MALAYSIA MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 165. PHILIPPINES MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. PHILIPPINES MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 167. PHILIPPINES MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 168. PHILIPPINES MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
  • TABLE 169. PHILIPPINES MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 170. PHILIPPINES MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 171. PHILIPPINES MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. PHILIPPINES MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
  • TABLE 173. PHILIPPINES MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 174. SINGAPORE MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. SINGAPORE MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 176. SINGAPORE MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 177. SINGAPORE MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
  • TABLE 178. SINGAPORE MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 179. SINGAPORE MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 180. SINGAPORE MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. SINGAPORE MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
  • TABLE 182. SINGAPORE MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 183. SOUTH KOREA MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. SOUTH KOREA MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 185. SOUTH KOREA MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 186. SOUTH KOREA MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
  • TABLE 187. SOUTH KOREA MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 188. SOUTH KOREA MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 189. SOUTH KOREA MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. SOUTH KOREA MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
  • TABLE 191. SOUTH KOREA MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 192. TAIWAN MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. TAIWAN MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 194. TAIWAN MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 195. TAIWAN MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
  • TABLE 196. TAIWAN MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 197. TAIWAN MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 198. TAIWAN MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
  • TABLE 199. TAIWAN MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
  • TABLE 200. TAIWAN MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 201. THAILAND MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 202. THAILAND MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 203. THAILAND MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 204. THAILAND MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
  • TABLE 205. THAILAND MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 206. THAILAND MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 207. THAILAND MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
  • TABLE 208. THAILAND MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
  • TABLE 209. THAILAND MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 210. VIETNAM MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 211. VIETNAM MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 212. VIETNAM MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 213. VIETNAM MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
  • TABLE 214. VIETNAM MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 215. VIETNAM MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 216. VIETNAM MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
  • TABLE 217. VIETNAM MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
  • TABLE 218. VIETNAM MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 228. EUROPE, MIDDLE EAST & AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 229. DENMARK MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 230. DENMARK MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 231. DENMARK MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 232. DENMARK MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
  • TABLE 233. DENMARK MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 234. DENMARK MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 235. DENMARK MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
  • TABLE 236. DENMARK MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
  • TABLE 237. DENMARK MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 238. EGYPT MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 239. EGYPT MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 240. EGYPT MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 241. EGYPT MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
  • TABLE 242. EGYPT MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 243. EGYPT MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 244. EGYPT MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
  • TABLE 245. EGYPT MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
  • TABLE 246. EGYPT MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 247. FINLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 248. FINLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 249. FINLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 250. FINLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
  • TABLE 251. FINLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 252. FINLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 253. FINLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
  • TABLE 254. FINLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
  • TABLE 255. FINLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 256. FRANCE MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 257. FRANCE MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 258. FRANCE MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 259. FRANCE MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
  • TABLE 260. FRANCE MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 261. FRANCE MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 262. FRANCE MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
  • TABLE 263. FRANCE MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
  • TABLE 264. FRANCE MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 265. GERMANY MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 266. GERMANY MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 267. GERMANY MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 268. GERMANY MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
  • TABLE 269. GERMANY MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 270. GERMANY MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 271. GERMANY MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
  • TABLE 272. GERMANY MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
  • TABLE 273. GERMANY MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 274. ISRAEL MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 275. ISRAEL MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 276. ISRAEL MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 277. ISRAEL MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
  • TABLE 278. ISRAEL MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 279. ISRAEL MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 280. ISRAEL MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
  • TABLE 281. ISRAEL MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
  • TABLE 282. ISRAEL MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 283. ITALY MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 284. ITALY MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 285. ITALY MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 286. ITALY MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
  • TABLE 287. ITALY MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 288. ITALY MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 289. ITALY MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
  • TABLE 290. ITALY MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
  • TABLE 291. ITALY MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 292. NETHERLANDS MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 293. NETHERLANDS MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 294. NETHERLANDS MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 295. NETHERLANDS MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
  • TABLE 296. NETHERLANDS MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 297. NETHERLANDS MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 298. NETHERLANDS MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
  • TABLE 299. NETHERLANDS MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
  • TABLE 300. NETHERLANDS MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 301. NIGERIA MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 302. NIGERIA MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 303. NIGERIA MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 304. NIGERIA MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
  • TABLE 305. NIGERIA MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 306. NIGERIA MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 307. NIGERIA MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
  • TABLE 308. NIGERIA MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
  • TABLE 309. NIGERIA MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 310. NORWAY MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 311. NORWAY MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 312. NORWAY MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 313. NORWAY MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
  • TABLE 314. NORWAY MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 315. NORWAY MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 316. NORWAY MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
  • TABLE 317. NORWAY MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
  • TABLE 318. NORWAY MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 319. POLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 320. POLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 321. POLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 322. POLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
  • TABLE 323. POLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 324. POLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 325. POLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
  • TABLE 326. POLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
  • TABLE 327. POLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 328. QATAR MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 329. QATAR MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 330. QATAR MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 331. QATAR MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
  • TABLE 332. QATAR MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 333. QATAR MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 334. QATAR MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
  • TABLE 335. QATAR MENINGOC